<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Proposed grading for CAR-T cell-related immune effector cell-associated neurotoxicity syndrome (ICANS) from the ASTCT</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Proposed grading for CAR-T cell-related immune effector cell-associated neurotoxicity syndrome (ICANS) from the ASTCT</h1>
<div class="graphic"><div class="figure"><div class="ttl">Proposed grading for CAR-T cell-related immune effector cell-associated neurotoxicity syndrome (ICANS) from the ASTCT</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Neurotoxicity domain</td> <td class="subtitle1">Grade 1</td> <td class="subtitle1">Grade 2</td> <td class="subtitle1">Grade 3</td> <td class="subtitle1">Grade 4</td> </tr> <tr class="divider_bottom"> <td>ICE score*</td> <td>7 to 9</td> <td>3 to 6</td> <td>0 to 2</td> <td>0 (patient is unarousable and unable to perform ICE)</td> </tr> <tr class="divider_bottom"> <td>Depressed level of consciousness<sup>¶</sup></td> <td>Awakens spontaneously</td> <td>Awakens to voice</td> <td>Awakens only to tactile stimulus</td> <td>Patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse; stupor or coma</td> </tr> <tr class="divider_bottom"> <td>Seizure</td> <td>N/A</td> <td>N/A</td> <td>Any clinical seizure, focal or generalized, that resolves rapidly, or nonconvulsive seizures on EEG that resolve with intervention</td> <td>Life-threatening prolonged seizure (&gt;5 minutes), or repetitive clinical or electrical seizures without return to baseline in between</td> </tr> <tr class="divider_bottom"> <td>Motor findings<sup>Δ</sup></td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td>Deep focal motor weakness such as hemiparesis or paraparesis</td> </tr> <tr class="divider_bottom"> <td>Elevated ICP/cerebral edema</td> <td>N/A</td> <td>N/A</td> <td>Focal/local edema on neuroimaging<sup>◊</sup></td> <td>Diffuse cerebral edema on neuroimaging, decerebrate or decorticate posturing, cranial nerve VI palsy, papilledema, or Cushing triad</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="5">ICE score definitions</td> </tr> <tr class="divider_bottom"> <td>Orientation</td> <td colspan="3">Orientation to year, month, city, hospital</td> <td>4 points</td> </tr> <tr class="divider_bottom"> <td>Naming</td> <td colspan="3">Ability to name 3 objects (eg, point to clock, pen, button)</td> <td>3 points</td> </tr> <tr class="divider_bottom"> <td>Following commands</td> <td colspan="3">Ability to follow simple commands (eg, "Show me 2 fingers" or "Close your eyes and stick out your tongue")</td> <td>1 point</td> </tr> <tr class="divider_bottom"> <td>Writing</td> <td colspan="3">Ability to write a standard sentence (eg, "Our national bird is the bald eagle")</td> <td>1 point</td> </tr> <tr> <td>Attention</td> <td colspan="3">Ability to count backwards from 100 by 10</td> <td>1 point</td> </tr> </tbody></table></div><div class="graphic_lgnd">ICANS grade is determined by the most severe event (ICE score, level of consciousness, seizure, motor findings, raised ICP/cerebral edema) not attributable to any other cause; for example, a patient with an ICE score of 3 who has a generalized seizure is classified as grade 3 ICANS.</div><div class="graphic_footnotes">ASTCT: American Society for Transplantation and Cellular Therapy (formerly the American Society for Blood and Marrow Transplantation); ICE: immune effector cell-associated encephalopathy (based on orientation, naming, ability to follow commands, writing, and attention; refer to UpToDate text); N/A: not applicable; EEG: electroencephalogram; ICP: intracranial pressure; CTCAE: Common Terminology Criteria for Adverse Events.<br/>* A patient with an ICE score of 0 (ie, not oriented, can't name 3 objects, can't follow simple commands, unable to write a sentence, and can't hold attention; refer to UpToDate text) may be classified as grade 3 ICANS if awake with global aphasia, but a patient with an ICE score of 0 may be classified as grade 4 ICANS if unarousable.<br/>¶ Depressed level of consciousness should be attributable to no other cause (eg, no sedating medication).<br/>Δ Tremors and myoclonus associated with immune effector cell therapies may be graded according to CTCAE version 5.0, but they do not influence ICANS grading.<br/><span class="lozenge">◊</span> Intracranial hemorrhage, with or without associated edema, is not considered a neurotoxicity feature and is excluded from ICANS grading. It may be graded according to CTCAE version 5.0.</div><div class="graphic_reference">Original table modified for this publication. From: Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 2019; 25:625. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 122197 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
